Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Zeria Aims at 50% Market Share for Asacol: President Ibe
November 30, 2009
- NDA for Liraglutide, Vildagliptin to Be Reviewed
November 30, 2009
- JDS to Include HbA1c in Its Diagnostic Criteria
November 30, 2009
- Sciele Pharma to Acquire Addrenex: Shionogi
November 30, 2009
- JPMA President Stresses the Need for Price Maintenance System
November 30, 2009
- Rohto Posts Record-High Sales Driven by Cosmetic Business
November 30, 2009
- Blopress Japan's Best-Selling Drug in 2nd Qtr: IMS Japan
November 30, 2009
- FJPWA President Expresses Great Concern about GRU WG's Recommendation
November 30, 2009
- JSA Revises Its GL on Prevention and Management of Asthma
November 30, 2009
- Growth of CRO Business Slows Down due to Megamergers: Mr Nakamura
November 30, 2009
- Non-clinical Evaluation of Anticancer Drugs Reaches Step 4 at ICH
November 30, 2009
- Business Improves for Hospitals and Worsens for GPs, Pharmacies
November 30, 2009
- Toho to Demand Fees to Makers for Services Using Meissa
November 30, 2009
- Chugai's Epogin Applied for Chemotherapy-Induced Anemia
November 30, 2009
- Xolair Recommended in JGL2009
November 30, 2009
- Eisai Launches Sedative-Hypnotic Lusedra in the US
November 30, 2009
- Astellas Applies for ASP8825 for RLS in Japan
November 30, 2009
- Vibativ Launched in the US: Astellas
November 30, 2009
- FDA Warns against Concurrent Use of Omeprazole and Plavix
November 30, 2009
- Alexion Pharma to Hire Up to 13 MCCs in Japan: President Strenger
November 30, 2009
ページ
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…